Trump Administration Targets Prescription Drug Costs
The Trump administration has announced the selection of 15 medications for the Medicare Drug Price Negotiation Program, aiming to significantly lower prescription drug costs for American patients. This initiative will utilize negotiations to determine new pricing, with changes set to take effect on January 1, 2028.
Medicare and Medicaid Administrator Dr. Mehmet Oz emphasized the importance of reducing costs for seniors and taxpayers who are currently burdened by soaring drug prices. “For too long, seniors and taxpayers have paid the price for skyrocketing prescription drug costs,” he stated during the announcement.
Background on the Drug Price Negotiation Program
This move is part of a broader strategy by the Trump administration to address high medication costs impacting American citizens. The current cycle follows two completed phases, which began negotiating prices for ten drugs set to take effect in 2026, and 15 additional drugs whose prices will change in 2027.
The selected drugs cover a wide range of medical conditions, from cancer and diabetes to arthritis and HIV. According to estimates, the revisions could result in billions of dollars in savings for patients relying on Medicare.
Selected Medications for Price Negotiation
The following 15 medications are included in the third cycle of negotiations:
- Anoro Ellipta: A treatment for Chronic Obstructive Pulmonary Disease (COPD).
- Biktarvy: A once-daily pill for HIV-1 infection.
- Botox; Botox Cosmetic: Used for chronic migraines and cosmetic purposes.
- Cimzia: An injection for autoimmune conditions like Crohn’s disease.
- Cosentyx: Used for treating plaque psoriasis and psoriatic arthritis.
- Entyvio: Treats ulcerative colitis and Crohn’s disease.
- Erleada: Oral medication for prostate cancer.
- Kisqali: For hormone-receptor-positive breast cancer.
- Lenvima: Treats various types of cancer.
- Orencia: Reduces symptoms of rheumatoid arthritis.
- Rexulti: For depression and schizophrenia.
- Trulicity: Treats type 2 diabetes and reduces heart disease risk.
- Verzenio: For specific types of breast cancer.
- Xeljanz; Xeljanz XR: Treats rheumatoid arthritis.
- Xolair: For allergic asthma and chronic hives.
Timeline for Upcoming Negotiations
The negotiations will unfold according to a structured timeline, beginning with a deadline for drug companies to sign agreements on February 28, 2026. Following that, manufacturers must provide specific data by March 1, 2026, for the negotiation process.
Public engagement sessions focusing on patient needs will occur in April 2026. By June 1, CMS will issue initial offers to the participating companies, which they will have the option to accept or counter. The negotiation process will culminate in final offers being extended by September 30, 2026.
Impact of Selected Drugs on Medicare Expenditure
From November 2024 to October 2025, the drug costs for selected medications accounted for approximately $27 billion in Medicare expenditures. This figure represents nearly 6% of all expenses related to Medicare Part B and Part D during that timeframe.
Interestingly, Botox, known for both medical and cosmetic usage, spent over $1.14 billion of that total, used by approximately 390,000 Medicare beneficiaries.
Reactions from Health Officials and Industry Experts
Health officials hailed the initiative as a significant step in addressing the burden of high medication costs. Dr. Oz remarked, “Under President Trump’s leadership, CMS is taking strong action to target the most expensive drugs in Medicare, negotiate fair prices, and make sure the system works for patients—not special interests. This approach delivers real savings while strengthening accountability across the program.”
Industry experts expressed cautious optimism regarding the long-term implications of price negotiations. Many believe that such negotiations, if executed effectively, could foster a more competitive market and drive prices down further, benefiting consumers in the long run.
Looking Ahead
With the third phase of the drug price negotiation program underway, officials anticipate that the revised prices will provide relief to many patients after they take effect in early 2028. Ongoing discussions and negotiations are expected to continue over the course of the next two years, leading to a potential overhaul of how drug prices are managed within the Medicare program.
The success of this initiative may set a precedent for future reforms in drug pricing across the healthcare system, with advocates calling for sustained efforts to keep patient costs manageable and predictable.
Concluding Remarks
As the Trump administration forges ahead with these negotiations, all eyes will be on the outcomes and broader effects on both Medicare and the pharmaceutical industry. The administration’s commitment to tackling sky-high prescription prices aims to establish a more equitable healthcare framework for all Americans.
Future updates will reveal the actual impacts of these negotiated prices on patients’ healthcare experiences, potentially leading to enhanced access to crucial medications.